We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Gets Complete Response Letter Over Chronic Rhinosinusitis Drug
AstraZeneca Gets Complete Response Letter Over Chronic Rhinosinusitis Drug
The FDA has sent AstraZeneca a Complete Response Letter (CRL) over its supplemental Biologics License Application (sBLA) for the company’s blockbuster Fasenra (benralizumab), as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP).